0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Research Letters |

Glucocerebrosidase Mutations and Risk of Parkinson Disease in Chinese Patients FREE

Eng-King Tan, MD; Justina Tong, BSc; Stephanie Fook-Chong, MSc; Yuen Yih, MD; Meng-Cheong Wong, MD; Ratnagopal Pavanni, MD; Yi Zhao, MD
Arch Neurol. 2007;64(7):1056-1058. doi:10.1001/archneur.64.7.1056.
Text Size: A A A
Published online

Gaucher disease (GD) is a recessive inherited glycolipid storage disorder caused by a deficiency of the lysosomal enzyme glucocerebrosidase (GBA).1 Recent observation of an association between Parkinson disease (PD) and GBA gene mutations in Ashkenazi Jewish patients has generated considerable scientific interest.2 However, data on this association in non–Ashkenazi Jewish populations is still limited.3,4 Two recent studies in white patients with PD reported a negative or questionable association with GBA mutations.3,4 The GBA L444P mutation appears to be the most common mutation among Chinese patients with GD in Taiwan.5 However, GD is extremely rare in our country. To our knowledge, there has not been a single reported case of GD in our population. Using a case-control methodology, we conducted a genetic screen of 2 common GBA mutations (L444P and N370S) in our ethnic Chinese patients with PD.

Our study included consecutive ethnic Chinese patients diagnosed with idiopathic PD by movement disorders neurologists at a tertiary referral center in Singapore. The PD diagnosis was made in accordance with the UK Parkinson's Disease Society Brain Bank clinical criteria. Controls were healthy individuals of similar age, sex, and race without neurodegenerative diseases and were examined by us. The institutional ethics committee approved the study, and informed consent was obtained from all study subjects. We extracted DNA from lymphocytes according to a standardized protocol. Allelic discrimination using the 5′ nuclease activity assay was adapted to detect the L444P and N370S mutations. Primers and probes were designed using Primer Express 1.5 software (Applied Biosystems, Foster City, California). The amplification reactions were carried out in an ABI Prism 7700 Sequence Detection System (Applied Biosystems) with 2 initial steps (50°C for 2 minutes followed by 95°C for 10 minutes) and 40 cycles of a 2-step polymerase chain reaction (95°C for 15 seconds, 60°C for 1 minute). After the polymerase chain reaction, allelic-specific fluorescence was measured on the ABI Prism 7700 Sequence Detection System (Applied Biosystems) using Sequence Detection System 1.7 software for allelic discrimination. Sequence analysis was used to confirm the genotypes for all the positive samples (Figure). The numerical and categorical variables were compared using a Fischer exact test and t test. Statistical significance was defined at P<.05.

Place holder to copy figure label and caption
Figure.

Sequence chromatograph showing the T-to-C mutation (L444P) (position indicated by vertical line).

Graphic Jump Location

A total of 678 subjects comprising 331 patients with PD and 347 controls similar in age and sex were analyzed. The mean ± SD age was 70.0 ± 11.0 years (range, 39-98 years) and 51.4% were men. The mean ± SD ages at onset of patients with PD and controls was 64.0 ± 10.0 years (range, 35-95 years) and 64.0 ± 12.0 years (range, 29-90 years), comprising 48.7% men.

The frequency of the L444P and N370S mutations in patients with PD and controls was 8 of 331 vs 0 of 347 (2.4% vs 0.0%, P = .003). All 8 patients with PD were heterozygous for the L444P mutation. However, the N370S mutation was not detected in all 778 subjects. Subset analysis revealed the association to be stronger in the group of subjects younger than 55 years (12.1% vs 0.0%, P = .004) compared with those older than 55 years (1.3% vs 0.0%, P = .06). The age at onset was lower in patients with PD with the L444P mutation compared with those without (49.0 ± 13.0 years; range, 29-70 years; vs 64.0 ± 11.0 years; range, 31-90 years; P = .002), and more women were present in the former group (87.5% vs 47.7%, P = .03).

Almost all patients with the L444P mutation presented with typical features of PD that were responsive to dopaminergic agents, and some developed levodopa-induced dyskinesias (Table). Previous mutational screening of the PARK1, PARK2, PARK6, PARK7, and PARK8 genes in these patients showed unremarkable findings.

Table Graphic Jump LocationTable. Clinical Features of Patients With Parkinson Disease (PD) With GBA Mutations

We found a significantly higher prevalence of the L444P mutation in our patients with PD compared with controls, and the association was stronger in younger subjects and in women. The zero prevalence in the controls appeared compatible with the extreme rarity of GD in our population. Six of the 8 affected patients with PD did not have a family history of PD and the remaining 2 were siblings. The mean age at onset of these patients was significantly younger than the age of patients with PD without GBA mutations. One study in Ashkenazi Jewish patients reported a younger age at onset in PD with mutations, but this was not observed by others.2,6

A wide spectrum of neurological manifestations, such as epilepsy, cerebellar ataxia, psychiatric symptoms, dementia, and parkinsonism, has been reported in GD. GBA mutations have also been reported in other Lewy body disorders.7 The typical PD presentation and disease progression in all our 8 affected patients with PD was compatible with recent observations in Ashkenazi Jewish patients. The pathophysiologic link between PD and GD could be due to the impaired degradation of α-synuclein aggregation as a result of lysosomal and proteasomal dysfunction.

Although the 2.4% frequency of the L444P GBA mutation in our patients with PD may appear low, this finding is significant due to the extreme rarity of GD in our population, supported by confirmation of the absence of this mutation among our healthy controls. While we cannot exclude the contribution of other rare GBA mutations, our study suggests that the L444P GBA mutation is associated with an increased risk of PD among the Chinese population.

Correspondence: Dr Tan, Department of Neurology, Singapore General Hospital, Outram Road, Singapore 169608 (gnrtek@sgh.com.sg).

Author Contributions:Acquisition of data: Tan, Tong, Fook-Chong, Yih, Wong, Pavanni, and Zhao. Analysis and interpretation of data: Tan. Drafting of the manuscript: Tan. Critical revision of the manuscript for important intellectual content: Tan, Tong, Fook-Chong, Yih, Wong, Pavanni, and Zhao. Administrative, technical, and material support: Tan, Tong, Fook-Chong, Yih, Wong, Pavanni, and Zhao. Study supervision: Tan, Tong, Fook-Chong, Yih, Wong, Pavanni, and Zhao.

Financial Disclosure: None reported.

Funding/Support: This study was supported by the National Medical Research Council and SingHealth.

Additional Contributions: Lee Wei-Ling, MD, and Ivy Ng, MD, provided assistance and feedback.

Lwin  AOrvisky  EGoker-Alpan  OLaMarca  MESidransky  E Glucocerebrosidase mutations in subjects with parkinsonism. Mol Genet Metab 2004;81 (1) 70- 73
PubMed Link to Article
Aharon-Peretz  JRosenbaum  HGershoni-Baruch  R Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N Engl J Med 2004;351 (19) 1972- 1977
PubMed Link to Article
Sato  CMorgan  ALang  AE  et al.  Analysis of the glucocerebrosidase gene in Parkinson's disease. Mov Disord 2005;20 (3) 367- 370
PubMed Link to Article
Toft  MPielsticker  LRoss  OAAasly  JOFarrer  MJ Glucocerebrosidase gene mutations and Parkinson disease in the Norwegian population. Neurology 2006;66 (3) 415- 417
PubMed Link to Article
Choy  FYHumphries  MLShi  H Identification of two novel and four uncommon missense mutations among Chinese Gaucher disease patients. Am J Med Genet 1997;71 (2) 172- 178
PubMed Link to Article
Aharon-Peretz  JBadarny  SRosenbaum  HGershoni-Baruch  R Mutations in the glucocerebrosidase gene and Parkinson disease: phenotype-genotype correlation. Neurology 2005;65 (9) 1460- 1461
PubMed Link to Article
Goker-Alpan  OGiasson  BIEblan  MJ  et al.  Glucocerebrosidase mutations are an important risk factor for Lewy body disorders. Neurology 2006;67 (5) 908- 910
PubMed Link to Article

Figures

Place holder to copy figure label and caption
Figure.

Sequence chromatograph showing the T-to-C mutation (L444P) (position indicated by vertical line).

Graphic Jump Location

Tables

Table Graphic Jump LocationTable. Clinical Features of Patients With Parkinson Disease (PD) With GBA Mutations

References

Lwin  AOrvisky  EGoker-Alpan  OLaMarca  MESidransky  E Glucocerebrosidase mutations in subjects with parkinsonism. Mol Genet Metab 2004;81 (1) 70- 73
PubMed Link to Article
Aharon-Peretz  JRosenbaum  HGershoni-Baruch  R Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N Engl J Med 2004;351 (19) 1972- 1977
PubMed Link to Article
Sato  CMorgan  ALang  AE  et al.  Analysis of the glucocerebrosidase gene in Parkinson's disease. Mov Disord 2005;20 (3) 367- 370
PubMed Link to Article
Toft  MPielsticker  LRoss  OAAasly  JOFarrer  MJ Glucocerebrosidase gene mutations and Parkinson disease in the Norwegian population. Neurology 2006;66 (3) 415- 417
PubMed Link to Article
Choy  FYHumphries  MLShi  H Identification of two novel and four uncommon missense mutations among Chinese Gaucher disease patients. Am J Med Genet 1997;71 (2) 172- 178
PubMed Link to Article
Aharon-Peretz  JBadarny  SRosenbaum  HGershoni-Baruch  R Mutations in the glucocerebrosidase gene and Parkinson disease: phenotype-genotype correlation. Neurology 2005;65 (9) 1460- 1461
PubMed Link to Article
Goker-Alpan  OGiasson  BIEblan  MJ  et al.  Glucocerebrosidase mutations are an important risk factor for Lewy body disorders. Neurology 2006;67 (5) 908- 910
PubMed Link to Article

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 33

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
JAMAevidence.com

The Rational Clinical Examination
Make the Diagnosis: Parkinsonism

The Rational Clinical Examination
Original Article: Does This Patient Have Parkinson Disease?